SB
NBIX icon

SIG Brokerage’s Neurocrine Biosciences NBIX Stock Holding History

SIG Brokerage’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Sell
2,618
-3,294
-56% -$489K 0.01% 692
2026
Q1 		$779K Buy
+5,912
New +$784K 0.02% 464

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SIG Brokerage's NBIX Position: Q2 2026 in Review

SIG Brokerage reduced its Neurocrine Biosciences (NBIX) stake by 56% in Q2 2026, selling an estimated $489K and leaving 2,618 shares worth $441K. The position accounts for 0.01% of the portfolio, ranked #692.

SIG Brokerage first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. The position peaked at $779K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SIG Brokerage held 2,618 shares of Neurocrine Biosciences worth $441K as of Q2 2026.
  • SIG Brokerage sold 3,294 Neurocrine Biosciences shares in Q2 2026, an estimated $489K.
  • Neurocrine Biosciences made up 0.01% of SIG Brokerage's portfolio in Q2 2026, its #692 holding.
  • SIG Brokerage first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • SIG Brokerage's Neurocrine Biosciences position peaked at $779K in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SIG Brokerage's 13F filing for Q2 2026, filed 14 Aug 2026.